Answers are grounded in this paper and cite their sources.
Fondaparinux is non-inferior to low molecular weight heparin with respect to risk of bleeding. The favorable safety profile of fondparinux supports its prophylactic use as an alternative to low molecular weight heparin after surgery for urological malignancy.
No takes yet. Share an insight, caveat, or question.
Hata et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: